Barclays PLC Takes Position in Guardian Pharmacy Services, Inc. (NYSE:GRDN)

Barclays PLC bought a new position in shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 18,500 shares of the company’s stock, valued at approximately $311,000.

Several other institutional investors have also modified their holdings of GRDN. Stephens Inc. AR purchased a new stake in Guardian Pharmacy Services during the 3rd quarter worth approximately $189,000. Point72 DIFC Ltd acquired a new stake in shares of Guardian Pharmacy Services during the third quarter worth approximately $573,000. Royce & Associates LP acquired a new stake in Guardian Pharmacy Services in the third quarter valued at $1,260,000. Foundry Partners LLC bought a new position in Guardian Pharmacy Services during the 3rd quarter valued at $1,680,000. Finally, Seven Grand Managers LLC bought a new position in Guardian Pharmacy Services during the 3rd quarter valued at $2,515,000.

Insider Activity

In other Guardian Pharmacy Services news, Director Steven D. Cosler purchased 7,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were bought at an average price of $21.22 per share, with a total value of $148,540.00. Following the completion of the acquisition, the director now owns 17,713 shares in the company, valued at approximately $375,869.86. This represents a 65.34 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Guardian Pharmacy Services Stock Down 0.5 %

NYSE GRDN opened at $19.79 on Friday. The firm has a 50-day simple moving average of $21.93. Guardian Pharmacy Services, Inc. has a one year low of $14.16 and a one year high of $25.74.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($2.00) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($2.19). The company had revenue of $314.39 million during the quarter, compared to analyst estimates of $303.21 million. Equities analysts forecast that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on GRDN shares. Stephens assumed coverage on shares of Guardian Pharmacy Services in a research note on Tuesday, October 22nd. They issued an “overweight” rating and a $21.00 target price on the stock. Truist Financial increased their target price on Guardian Pharmacy Services from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Finally, Raymond James assumed coverage on Guardian Pharmacy Services in a research report on Monday, October 21st. They issued an “outperform” rating and a $21.00 target price for the company.

Guardian Pharmacy Services Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.